Bicara Therapeutics Stock (BCAX.US) Real-time Quotes - Financial Data - Analyst Ratings

Company Encyclopedia

Bicara Therapeutics

BCAX.US

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

1.925 T

BCAX.USMarket value -Rank by Market Cap -/-

Valuation analysis

P/E

10Y

P/E

Industry Ranking

-/-

P/E
Price
High
Median
Low

P/B

10Y

P/B

Industry Ranking

-/-

P/B
Price
High
Median
Low

P/S

10Y

P/S

Industry Ranking

-/-

P/S
Price
High
Median
Low

Dividend Yield

10Y

Dividend Yield

Industry Ranking

-/-

Dividend Yield
Price
High
Median
Low

Institutional View & Shareholder

Analyst Ratings

Rating

Percentage

Price
--
Highest
--
Lowest
--

Shareholder

Ownership	%Owned	Share Chg	Report Date
RA Capital Management, L.P.	12.7%	No Change	30/09/2025
Biocon Limited	10.08%	No Change	16/09/2024
Artal Group S.A.	9.52%	No Change	30/09/2025
Vestal Point Capital, LP	9.31%	100.00 K	30/09/2025
Red Tree Venture Capital	5.79%	No Change	30/09/2025
TPG Capital, L.P.	5.5%	No Change	30/09/2025
Deep Track Capital, LP	4.43%	No Change	30/09/2025
BlackRock, Inc.	4.22%	200.30 K	30/09/2025
T. Rowe Price Group, Inc.	4.05%	69.83 K	30/09/2025
Omega Fund Management, LLC	4.02%	No Change	30/09/2025

News

Bicara Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

LB filings·11/11/2025 05:50

BCAX

-1.73%

LB filings·11/11/2025 05:50

BCAX

-1.73%

Bicara Therapeutics | 8-K: FY2025 Q3 Revenue: USD 0

LB filings·11/10/2025 20:34

BCAX

-1.73%

LB filings·11/10/2025 20:34

BCAX

-1.73%

Bicara Therapeutics | 10-Q: FY2025 Q2 EPS Beats Estimate at USD -0.5

LB filings·08/13/2025 04:04

BCAX

-1.73%

LB filings·08/13/2025 04:04

BCAX

-1.73%

Bicara Therapeutics | 8-K: FY2025 Q2 EPS Beats Estimate at USD -0.5

LB filings·08/12/2025 19:42

BCAX

-1.73%

LB filings·08/12/2025 19:42

BCAX

-1.73%

Top 10 US Stock Losers (5.23)

Bicara Therapeutics(BCAX) fell 40.8%, with a trading turnover 63.6 Million USD, and a year-to-date fell 46.8%. Deckers Outdoor(DECK) fell 19.86%, with a trading turnover 2.0 Billion USD, and a year-to-date fell 50.2%. Miniso(MNSO) fell 17.58%, with a trading turnover 165.7 Million USD, and a year-to-date fell 21.9%.

LB Select·05/24/2025 06:00

LB Select·05/24/2025 06:00